NVS240920C110000
- 5.99
- +0.99+19.80%
Novartis AG Newsroom
J&J, Roche Come Out on Top in S&P Ratings of Strongest Pharma Companies
Trending Stocks This Week as U.S. Equities Notch Their Best Week of 2024
Top Gap Ups and Downs on Friday: SONY, IBN, DEO and More
Top Gap Ups and Downs on Thursday: WMT, CSCO, MUFG and More
Medicare Negotiates Lower Prices for 10 High-cost Drugs
Big Pharma: The Government Revealed Its List of Negotiated Drug Prices. Here Are the Reactions.
Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?
Negotiations on pharmaceutical prices in the United States have resulted in significant price reductions for ten key medications with the highest reduction approaching 80%.
According to the inflation reduction bill of the Biden administration, the final negotiated prices of the top 10 pharmaceuticals in Part D of federal medical insurance have been determined and announced.
Biden Administration Releases Prices of 10 Drugs in Medicare Negotiations
U.S. Announces Final Drug Prices After Medicare Negotiations
U.S. Government Targets $6B in Saving From First Medicare Drug Price Negotiations
Open Source Securities: Bullish on the opportunity of PCSK9 inhibitors in the lipid-lowering market.
Bullish on the opportunity of PCSK9 inhibitors in the lipid-lowering market, with a focus on the market potential of siRNA drugs with higher adherence. Leading companies with strategic layout are expected to benefit.
Top Gap Ups and Downs on Wednesday: TM, BHP, RIO and More
Novartis Could Slash Guidance Amid Generic Heart-Drug Competition -- Market Talk
Top Gap Ups and Downs on Tuesday: HDB, SONY, SBUX and More
Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug
Novartis Fails to Get Court Order to Block Generic Heart Medication Launch
Top Gap Ups and Downs on Monday: PBR, CI, SBUX and More
Fed Court Rules Against Novartis in Generic Entresto Case: Report
Top Gap Ups and Downs on Friday: IX, TTWO, EXPE and More